Short answer
TriSalus Life Sciences, Inc. (TLSI) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $11M (up 1.7% year over year) with net income of −$9M.
Q2 2026 key financials · XBRL
- Revenue
- $11M
- +1.7% YoY · +28.2% QoQ
- Net income
- −$9M
- −10.8% YoY · −696.9% QoQ
- Operating margin
- -86.0%
- Gross margin
- 86.8%
- EPS (diluted)
- −$0.17
- +34.6% YoY · −666.7% QoQ
Source: XBRL data from the TriSalus Life Sciences, Inc. (TLSI) Q2 2026 10-Q on SEC EDGAR. USD.
TriSalus Life Sciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $11.407M, up 1.7% YoY from $11.213M, primarily PEDD infusion-system sales
- Gross margin 86.8% vs 83.9% YoY, driven by lower cost per TriNav unit
- Sales and marketing $11.416M, up 59.4% YoY; only reportable segment, TriNav product family
- Cash and equivalents $46.3M at June 30, 2026 vs $20.4M December 31, 2025; operating cash use $16.6M
- Management expects continued operating losses; clinical update planned second half 2026 and additional capital may be required
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Credit agreement amendment filed with OrbiMed, indicating continued financing and debt-related exposure
- No newly disclosed regulatory, legal, operational, competitive, market, liquidity, currency, or concentration risks in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TriSalus Life Sciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.